ThinkEquity initiated coverage on PetVivo Holdings with a new price target
$PETV
Medical/Dental Instruments
Health Care
ThinkEquity initiated coverage of PetVivo Holdings with a rating of Buy and set a new price target of $7.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/12/2021 | $7.00 | Buy | ThinkEquity |
ThinkEquity initiated coverage of PetVivo Holdings with a rating of Buy and set a new price target of $7.00
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
10-Q - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
MINNEAPOLIS, MN, US, Nov. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTC ID: PETVW)), through its wholly owned subsidiary Petvivo Animal Health, a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, reported results for its second quarter and first half of fiscal year 2026 ended September 30, 2025. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call today at 5:00 p.m. Eastern time to discuss the results for the quarter, followed by a question-and-answer session (see dial-in information below). Fiscal Q2 Financial Highlights Revenues totaled
MINNEAPOLIS, MN, US, Nov. 07, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)) and its wholly-owned subsidiary Petvivo Animal Health, Inc., a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, will hold a conference call on Friday, November 14, 2025 at 5:00 p.m. Eastern time to discuss results for the fiscal second quarter ended September 30, 2025. The financial results will be issued in a press release prior to the call. PetVivo management will host the presentation, followed by a question-and-answer period. The Fiscal Second Quarter 2026 conference call information is as follows: Date: Friday,
MINNEAPOLIS, MN, US, Oct. 28, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID PETVW)), in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., both emerging biomedical device companies focused on the commercialization of innovative medical therapeutics for companion animals and animal athletes is pleased to announce that Josh Ruben has joined the Company's Board of Directors. "We are honored to welcome Josh Ruben to our Board of Directors," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "Josh brings a wealth of experience in healthcare finance, capital markets, and corporate strategy, with a proven track record of executing multi-b
MINNEAPOLIS, MN, US, Oct. 28, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID PETVW)), in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., both emerging biomedical device companies focused on the commercialization of innovative medical therapeutics for companion animals and animal athletes is pleased to announce that Josh Ruben has joined the Company's Board of Directors. "We are honored to welcome Josh Ruben to our Board of Directors," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "Josh brings a wealth of experience in healthcare finance, capital markets, and corporate strategy, with a proven track record of executing multi-b
Minneapolis, MN, June 06, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, OTC:PETVW), an emerging biomedical device company focused on animal health, today announced a strategic collaboration with Commonwealth, the syndicated ownership group behind 2023 Kentucky Derby winner Mage, and 2022 Dubai World Cup Champion Country Grammer. The partnership centers on the clinical use and promotion of SPRYNG® with OsteoCushion® Technology, PetVivo's cutting-edge intra-articular device designed to support joint health and durability, and Precise PRP™, a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians in elite equine athletes. As part of t
PetVivo Board Appoints Eldred as Executive Director to Lead Company Product Commercialization and Operations MINNEAPOLIS, MN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW)), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Mike Eldred as the Company's Commercialization and Operations Advisor. His appointment as an Executive Director by the Company's Board of Directors draws upon Mr. Eldred's 30 years of executive experience in animal health and the veterinary industry to ramp up its product development and sales efforts. For the past 20 years, Mr. Eldred served as President of North American Operations for Dech
MINNEAPOLIS, MN, US, Nov. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTC ID: PETVW)), through its wholly owned subsidiary Petvivo Animal Health, a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, reported results for its second quarter and first half of fiscal year 2026 ended September 30, 2025. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call today at 5:00 p.m. Eastern time to discuss the results for the quarter, followed by a question-and-answer session (see dial-in information below). Fiscal Q2 Financial Highlights Revenues totaled
MINNEAPOLIS, MN, US, Nov. 07, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)) and its wholly-owned subsidiary Petvivo Animal Health, Inc., a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, will hold a conference call on Friday, November 14, 2025 at 5:00 p.m. Eastern time to discuss results for the fiscal second quarter ended September 30, 2025. The financial results will be issued in a press release prior to the call. PetVivo management will host the presentation, followed by a question-and-answer period. The Fiscal Second Quarter 2026 conference call information is as follows: Date: Friday,
MINNEAPOLIS, MN, US, Aug. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., including its wholly-owned subsidiary Petvivo Animal Health, Inc. (OTCQX:PETV, OTC ID: PETVW)), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, reported results for its first quarter of fiscal year 2026 ended June 30, 2025. All comparisons are to the previous year first quarter period ending June 30, 2024, unless otherwise noted. The company will hold a conference call today, August 14, 2025, at 5:00 p.m. Eastern time to discuss the results for the quarter, followed by a question-and-answer session (see dial-in information below). Fiscal Q1
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)